Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome
- 28 June 2008
- journal article
- Published by Wiley in BJU International
- Vol. 102 (2) , 198-202
Abstract
OBJECTIVE: To evaluate the factors affecting outcome and the pathological findings in patients who had retroperitoneal lymph node dissection (pcRPLND) after chemotherapy with elevated tumour markers, as such patients have an unfavourable prognosis, with further salvage chemotherapy being the usual treatment of choice. PATIENTS AND METHODS: Information on the preoperative treatment, tumour markers, histopathology and outcome data of the patients who had pcRPLND were extracted from the hospital databases. Survival was analysed using the Kaplan‐Meier method and multivariate analysis with Cox regression model. RESULTS: In all, 358 patients had pcRPLND between September 1992 and April 2006, by one surgeon. In 48 patients the tumour markers were elevated at the time of surgery, they were on a ‘rising trend’ in 26 (54%) and ‘downward or stable’ trend in 22 (46%). The overall incidence of active germ cell tumour, differentiated teratoma and necrosis in the resected specimens was 58%, 25% and 17%, respectively. The median follow‐up was 51.5 months and the overall 5‐year survival was 69%. The favourable prognostic factors assessed by univariate analysis were elevation of α‐fetoprotein alone, complete resection of residual disease, histological finding of differentiated teratoma in the resected tissues and normalization of tumour markers after pcRPLND. By multivariate analysis the only statistically significant independent survival factor was the normalization of the tumour markers after pcRPLND. CONCLUSION: For selected patients with elevated tumour markers after chemotherapy, RPLND can offer a significant chance of cure with no need for further chemotherapy. The patients most likely to benefit are those with elevations of α‐fetoprotein alone. In this group, pcRPLND can offer the prospect of long‐term survival and should be considered in the management of selected patients.Keywords
This publication has 15 references indexed in Scilit:
- Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancerUrologic Oncology: Seminars and Original Investigations, 2005
- Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node DissectionJournal of Clinical Oncology, 2005
- Recent Advances in Conventional-Dose Salvage Chemotherapy in Patients with Cisplatin-Resistant or Refractory Testicular Germ Cell TumorsEuropean Urology, 2005
- Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markersCancer, 2003
- Metastatic nonseminomatous germ cell tumors of the testisCancer, 2002
- Surgery as salvage therapy in chemotherapy‐resistant nonseminomatous germ cell tumoursBritish Journal of Urology, 1998
- Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy aloneUrology, 1997
- Postchemotherapeutic surgery for metastatic testicular germ cell tumors: Results of extended primary chemotherapy and limited surgeryUrology, 1994
- Surgical resection in patients withnonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapyUrology, 1994
- Para‐aortic Lymphadenectomy after Chemotherapy for Metastatic Non‐seminomatous Germ Cell Tumours: Prognostic Value and Therapeutic BenefitBritish Journal of Urology, 1993